FierceBiotech

Next-gen T-cell cancer player Neogene raises $110M with help from some big-name players

A new neoantigen T-cell player has launched with Neogene Therapeutics nabbing a major $110 million series A. The funding haul, a significant sum for a first round, was led by by EcoR1 Capital, Jeito ...
FierceBiotech

Neogene adds ex-Roche director as CMO after snagging Bristol Myers, Arcellx vets

Raphaël Rousseau, M.D., Ph.D., is the latest biopharma vet to land at transatlantic biotech Neogene Therapeutics, where he joins a leadership bench of Kite and Bristol Myers Squibb veterans. Rousseau ...
EurekAlert!

To establish a timescale for more than 10 million years ago

The timescale is the base to reconstruct the history of the Earth and the biological evolution. A research on a chronostratigraphic sequence of the Chinese Neogene with accurate geological datings was ...
Business Wire

Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors

SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a global biotechnology company focused on discovering, developing, and manufacturing novel, transformative TCR therapies ...
Business Wire

Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors

NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...